124 related articles for article (PubMed ID: 33648413)
1. Expression levels of HLA-DR in acute myeloid leukemia: implications for antigenicity and clinical outcome.
Roerden M; Märklin M; Salih HR; Bethge WA; Klein R; Rammensee HG; Nelde A; Walz JS
Leuk Lymphoma; 2021 Aug; 62(8):1907-1919. PubMed ID: 33648413
[TBL] [Abstract][Full Text] [Related]
2. [Immunologic characteristics and prognosis of acute myeloid leukemia M1].
Zhao F; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):687-91. PubMed ID: 17708783
[TBL] [Abstract][Full Text] [Related]
3. HLA-DR antigen-negative acute myeloid leukemia.
Wetzler M; McElwain BK; Stewart CC; Blumenson L; Mortazavi A; Ford LA; Slack JL; Barcos M; Ferrone S; Baer MR
Leukemia; 2003 Apr; 17(4):707-15. PubMed ID: 12682628
[TBL] [Abstract][Full Text] [Related]
4. The MHC-II antigen presentation machinery and B7 checkpoint ligands display distinctive patterns correlated with acute myeloid leukaemias blast cells HLA-DR expression.
Antohe I; Tanasa MP; Dăscălescu A; Dănăilă C; Titieanu A; Zlei M; Ivanov I; Sireteanu A; Cianga P
Immunobiology; 2021 Jan; 226(1):152049. PubMed ID: 33352400
[TBL] [Abstract][Full Text] [Related]
5. [The immunophenotypic and clinical characteristics of NPM1 mutated acute myeloid leukemia patients].
Liu YR; Chang Y; Ruan GR; Qin YZ; Lai YY; Shi HX; Wang YZ; Li LD; Jiang B; Li JL
Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):98-103. PubMed ID: 23611213
[TBL] [Abstract][Full Text] [Related]
6. Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses.
van Luijn MM; Chamuleau ME; Thompson JA; Ostrand-Rosenberg S; Westers TM; Souwer Y; Ossenkoppele GJ; van Ham SM; van de Loosdrecht AA
Haematologica; 2010 Mar; 95(3):485-93. PubMed ID: 19903675
[TBL] [Abstract][Full Text] [Related]
7. Normal karyotype acute myeloid leukemia with the CD7+ CD15+ CD34+ HLA-DR + immunophenotype is a clinically distinct entity with a favorable outcome.
Iriyama N; Asou N; Miyazaki Y; Yamaguchi S; Sato S; Sakura T; Maeda T; Handa H; Takahashi M; Ohtake S; Hatta Y; Sakamaki H; Honda S; Taki T; Taniwaki M; Miyawaki S; Ohnishi K; Kobayashi Y; Naoe T
Ann Hematol; 2014 Jun; 93(6):957-63. PubMed ID: 24441947
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow overexpression of SNAI1 is an early indicator of intrinsic drug resistance in patients with de novo acute myeloid leukemia.
Gouda MBY; Hassan NM; Kandil EI
J Gene Med; 2023 May; 25(5):e3443. PubMed ID: 35900907
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Analysis of CD4
Hyun YS; Jo HA; Lee YH; Kim SM; Baek IC; Sohn HJ; Cho HI; Kim TG
Front Immunol; 2020; 11():602014. PubMed ID: 33658991
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of acute myeloid leukemia without HLA-DR expression.
Moon H; Lee S; Huh J; Chung WS
Korean J Lab Med; 2007 Oct; 27(5):313-7. PubMed ID: 18094594
[TBL] [Abstract][Full Text] [Related]
11. Positive and negative predictive values of HLA-DR and CD34 in the diagnosis of acute promyelocytic leukemia and other types of acute myeloid leukemia with recurrent chromosomal translocations.
Promsuwicha O; Auewarakul CU
Asian Pac J Allergy Immunol; 2009 Dec; 27(4):209-16. PubMed ID: 20232575
[TBL] [Abstract][Full Text] [Related]
12. Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin.
Narayan R; Olsson N; Wagar LE; Medeiros BC; Meyer E; Czerwinski D; Khodadoust MS; Zhang L; Schultz L; Davis MM; Elias JE; Levy R
PLoS One; 2019; 14(7):e0219547. PubMed ID: 31291378
[TBL] [Abstract][Full Text] [Related]
13. Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells.
Nelde A; Schuster H; Heitmann JS; Bauer J; Maringer Y; Zwick M; Volkmer JP; Chen JY; Stanger AMP; Lehmann A; Appiah B; Märklin M; Rücker-Braun E; Salih HR; Roerden M; Schroeder SM; Häring MF; Schlosser A; Schetelig J; Schmitz M; Boerries M; Köhler N; Lengerke C; Majeti R; Weissman IL; Rammensee HG; Walz JS
Blood Cancer Discov; 2023 Nov; 4(6):468-489. PubMed ID: 37847741
[TBL] [Abstract][Full Text] [Related]
14. [Clinicopathological features in HLA-DR-negative acute myeloid leukemia].
Muroi K; Yoshida M; Suzuki T; Amemiya Y; Hatake K; Miura Y
Rinsho Ketsueki; 1997 Aug; 38(8):631-7. PubMed ID: 9311267
[TBL] [Abstract][Full Text] [Related]
15. Comparative profiling of HLA-DR and HLA-DQ associated factor VIII peptides presented by monocyte-derived dendritic cells.
Peyron I; Hartholt RB; Pedró-Cos L; van Alphen F; Brinke AT; Lardy N; Meijer AB; Voorberg J
Haematologica; 2018 Jan; 103(1):172-178. PubMed ID: 29025906
[TBL] [Abstract][Full Text] [Related]
16. Immunophenotype distinction between acute promyelocytic leukaemia and CD15- CD34- HLA-DR- acute myeloid leukaemia with nucleophosmin mutations.
Ferrari A; Bussaglia E; Úbeda J; Facchini L; Aventin A; Sierra J; Nomdedéu JF
Hematol Oncol; 2012 Sep; 30(3):109-14. PubMed ID: 21812014
[TBL] [Abstract][Full Text] [Related]
17. HLA class I and class II antigen associations in acute leukaemias.
Navarrete C; Alonso A; Awad J; McCloskey D; Ganesan TS; Amess J; Lister TA; Festenstein H
J Immunogenet; 1986; 13(2-3):77-84. PubMed ID: 3469278
[TBL] [Abstract][Full Text] [Related]
18. Pattern of expression of HLA-DR and HLA-DQ antigens and mRNA in myeloid differentiation.
Amatruda TT; Bohman R; Ranyard J; Koeffler HP
Blood; 1987 Apr; 69(4):1225-36. PubMed ID: 3103718
[TBL] [Abstract][Full Text] [Related]
19. Significance of the expression of major histocompatibility complex class II antigen, HLA-DR and -DQ, with recurrence of papillary thyroid cancer.
Jo YS; Lee JC; Li S; Choi YS; Bai YS; Kim YJ; Lee IS; Rha SY; Ro HK; Kim JM; Shong M
Int J Cancer; 2008 Feb; 122(4):785-90. PubMed ID: 17957790
[TBL] [Abstract][Full Text] [Related]
20. Molecular identification of the HLA-DRB1-DQB1 for diagnosis and follow-up of acute leukemias.
Fernandes TA; Fukai R; Souza CA; Lorand-Metze I; Magna LA; Kraemer MH
Blood Cells Mol Dis; 2010; 44(2):69-73. PubMed ID: 20051322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
